Amgen reported impressive progress across its product lines in Q4. The standout performer was Repatha, whose sales increased 45% year over year to $606 million thanks to effective volume growth ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

What Happened: Grygiel's recent move involves selling 1,589 shares of Amgen. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Friday. The total ...

Amgen expects phase 3 data later this year for atopic dermatitis drug rocatinlimab and gastric cancer drug bemarituzumab and also data for Repatha in primary prevention. Bears say: A clinical hold ...

Repatha and EVENITY showed significant growth, with Repatha sales increasing by 36% to over $2.2 billion. Amgen Inc (NASDAQ:AMGN) successfully launched TEPEZZA in Japan and plans to expand into ...